

(I)

to the mammal.

12. The method according to Claim 11, wherein the mammal is a human.

13. A method of treating a mammal suffering from a disease chosen from unstable angina pectoris, acute coronary syndrome, heart failure, myocardial infarction, thrombosis, peripheral artery occlusive disease, restenosis, and endothelial damage after PTCA, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



(I)

to the mammal.

14. The method according to Claim 13, wherein the mammal is a human.

15. A method of treating a mammal suffering from a cardiovascular disease, which method comprises administering a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



(I)

and a pharmaceutically acceptable carrier to the mammal.

16. The method according to Claim 15, wherein the mammal is a human.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

17. The method according to Claim 15, wherein the pharmaceutical preparation is in the form of a pill, tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic system, nasal spray, aerosol mixture, microcapsule, implant or rod.

18. The method according to Claim 17, wherein the tablet is chosen from a lacquered tablet and a sugar-coated tablet.

19. A method of treating a mammal suffering from a disease chosen from unstable angina pectoris, acute coronary syndrome, heart failure, myocardial infarction, thrombosis, peripheral artery occlusive disease, restenosis, and endothelial damage after PTCA, which method comprises administering a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



(I)

and a pharmaceutically acceptable carrier to the mammal.

20. The method according to Claim 19, wherein the mammal is a human.

21. The method according to Claim 20, wherein the pharmaceutical preparation is in the form of a pill, tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic system, nasal spray, aerosol mixture, microcapsule, implant or rod.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

22. The method according to Claim 21, wherein the tablet is chosen from a lacquered tablet and a sugar-coated tablet.

23. A method of treating a mammal suffering from erectile dysfunction or osteoporosis, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



(I)

to the mammal.

24. The method according to Claim 23, wherein the mammal is a human.

25. A method of treating a mammal suffering from erectile dysfunction or osteoporosis, which method comprises administering a pharmaceutical preparation comprising an effective amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



(I)

and a pharmaceutically acceptable carrier to the mammal.

26. The method according to Claim 25, wherein the mammal is a human.

27. The method according to Claim 25, wherein the pharmaceutical preparation is in the form of a pill, tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com